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days. Following HCC diagnosis, total insurer costs increased by 6-fold ($1695 v 
$9983; p < 0.0001) and total patient costs increased by 4-fold ($151 v $575; p < 
0.0008). For insurers, the majority of these increases were due to hospital visits: 56% 
due to an 8-fold increase in hospitalization costs ($668 v $5273; p < 0.0001), 1% due 
to a 3-fold increase in emergency room (ER) costs ($27 v $71; p = 0.66), and 23% 
due to a 6-fold increase in other hospital outpatient costs ($418 v $2359; p < 0.0001). 
Outpatient and other costs comprised 4–9% of the total cost increase. Similarly for 
patients, the majority of cost increases were due to hospital visits: 43% due to a 9-fold 
increase in hospitalization costs ($22 v $207; p < 0.0001), 0.25% due to a 20% 
increase in ER costs ($5 v $6; p = 0.35), and 38% due to a 5-fold increase in other 
hospital outpatient costs ($39 v $200; p < 0.0001). Outpatient and other costs com-
prised 5–7% of the total cost increase. CONCLUSIONS: Insurer and patient costs 
increase substantially following HCC diagnosis, primarily due to hospitalizations. 
Future therapies should demonstrate improved disease control to reduce this burden 
for insurers and patients.
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OBJECTIVES: To compare health care resource utilization and costs associated with 
dasatinib versus nilotinib treatment as second-line therapies in CML patients. 
METHODS: Two claims databases were combined (MarketScan and Ingenix Impact, 
January 2002–December 2008) to identify patients diagnosed with CML (ICD-9 code 
205.1x) and received ≥1 prescription of dasatinib or nilotinib. Patients were required 
to have continuous enrollment ≥1 month prior to and after the index date. The index 
date was deﬁned as the ﬁrst prescription for dasatinib or nilotinib. Patients were fol-
lowed for up-to 6 months from the index date to the earliest of the termination of 
health care plan enrollment, or end of data availability. Negative binomial regression 
models were used to compare health care resource utilization between the two groups. 
Results were reported as unadjusted and adjusted incidence rate ratios (IRR). Health 
care costs were compared and reported as unadjusted and adjusted cost differences. 
These were estimated for each cost component using generalized linear models or 
two-part models. Multivariate regressions controlled for age, gender, and CML disease 
complexity. RESULTS: A total of 230 CML patients receiving a second-line TKI (186 
dasatinib and 44 nilotinib) were studied. During the study period, dasatinib patients 
had signiﬁcantly more medical visits (IRR = 1.32, p = .028). Dasatinib patients had 
36% more hospital days but the difference was not statistically signiﬁcant (IRR = 1.36, 
p = 0.664). Over the 6–month follow-up period, patients on dasatinib incurred 
$18,328 (p < .001) more in total medical services and $6,367 (p = 0.04) less in phar-
macy costs, resulting in a higher net total health care cost of $12,039 (p = .035). The 
difference in medical costs was mainly explained by the difference of inpatient costs 
($12,480; p = < .001) and outpatient costs ($5,035; p = .001). CONCLUSIONS: 
Among CML patients treated with a second-line TKIs, dasatinib patients incurred 
higher total health care costs and more frequent health care resource utilization than 
nilotinib patients.
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OBJECTIVES: To study health care resource utilization and costs associated with 
long-term non-adherence to imatinib in CML patients. METHODS: Two large admin-
istrative claims databases were combined (MarketScan and Ingenix Impact, January 
2002-July 2008) to identify patients diagnosed with CML (ICD-9 code 205.1x). 
Patients with ≥2 imatinib prescriptions and continuous enrollment (≥6 months prior 
to and ≥1month post index date) were selected. Patients were followed for up to 3 
years after the index date. A longitudinal retrospective open-cohort design was used 
to measure patients’ adherence to imatinib repeatedly over time. Imatinib treatment 
periods were divided into 90-day intervals. Treatment intervals were categorized as 
adherent (MPR ≥85%) or non-adherent (MPR < 85%). Patients’ health care utilization 
and costs were compared between adherent and non-adherent intervals. Multivariate 
regression models were used to compare rates of inpatient admissions, outpatient 
visits, and emergency room visits, controlling for clinical and demographic character-
istics. Additional regression models including past cumulative MPR were used to 
assess the long-term impact of non-adherence. RESULTS: For the 1877 CML patients 
in the study, there were 6175 adherent and 3163 non-adherent intervals. Only 34% 
of patients were fully adherent throughout the observation period. During non-
adherent intervals, patients incurred signiﬁcantly more inpatient (IRR = 2.76, p < 
0.001), ER (IRR = 1.25, p = 0.021), and outpatient (IRR = 1.09 p = 0.001) visits. 
Though non-adherence was associated with lower pharmacy cost ($3053 p < 0.001), 
this difference was outweighed by higher medical costs ($4531 p < 0.001), resulting 
in a net cost increase ($1477 (p < 0.001). Patients who were adherent throughout 
their observation period incurred an average cost of $11,759 per interval, compared 
to $13,773 for patients who were not always adherent. In patients who had not 
always been adherent (past cumulative MPR < 85%) an adherent interval cost $1,239 
(p = .002) more, while another non-adherent interval cost $2122 (p < 0.001) more 
compared to an adherent interval in patients who had been adherent. CONCLU-
SIONS: Imatinib non-adherence is associated with long-term negative economic 
consequences.
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OBJECTIVES: Alemtuzumab has been demonstrated to reduce the amount of malig-
nant lymphocytes in patients with chronic lymphocytic leukemia (CLL). The current 
study aimed to quantify the incremental cost to Medicare of treating CLL patients 
with alemtuzumab. METHODS: Claims records (1999–2007) from the Medicare 5% 
national sample were analyzed. Patients with continuous enrollment for ≥3 months 
prior to their ﬁrst observed claim with a CLL diagnosis, ≤2 malignancies, and ≥1 claim 
for alemtuzumab were included. A pre-post design was used to quantify the incremen-
tal costs associated with alemtuzumab by calculating health care costs within 6 months 
after alemtuzumab initiation relative to the 6-month period before alemtuzumab initia-
tion. Mean monthly (per-patient per-month, PPPM) costs were calculated and were 
grouped by sites of care, service type, tests and procedures, treatment and drugs, and 
by adverse events. Statistical comparisons between the pre- and post-treatment periods 
were based on paired Student t-tests. RESULTS: A total of 81 CLL patients treated 
with alemtuzumab formed the study population. The mean age was 75.2 years and 
females represented 38.3%. Patients were observed for an average of 50 months and 
mean time between the ﬁrst CLL diagnosis and initiation of alemtuzumab treatment 
was 36 months. After alemtuzumab initiation, mean total health care costs increased 
from $4,272 to $10,385 PPPM (P < 0.0001). Patients had a mean of 11.8 claims for 
alemtuzumab and the mean cost for alemtuzumab was $4,006 PPPM or 39% of total 
costs. PPPM costs associated with diagnostic codes for cytopenia, infection, and 
cardiac dysfunction were greater during the post- compared with the pre-alemtuzumab 
period (cytopenia: $1,658 vs. $4,114; infection: $107 vs. $841; cardiac dysfunction: 
$766 vs. $1,692; P < 0.05 for all). CONCLUSIONS: Amongst a cohort of Medicare 
fee-for-service patients with CLL, alemtuzumab was associated with a signiﬁcant 
increase in health care costs in the 6 months after initiation of therapy.
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OBJECTIVES: This study estimates the costs of AIs sunitinib, sorafenib, and bevaci-
zumab using economic modeling based on recorded health care resource utilization 
from medical charts. METHODS: Non-trial mRCC patients, ≥18 years, who received 
≥1 prescription for sunitinib (n = 57) or sorafenib (n = 62) or ≥1 intravenous admin-
istration of bevacizumab (n = 25) after Janaury 1, 2005 as ﬁrst-line AI were included. 
Total per-patient-per-month (PPPM) costs (US$2008) included costs of AI drugs, 
ofﬁce visits, procedures, and treatment of adverse events (AE) resulting in hospitaliza-
tion or emergency room (ER) visits. AI drug costs were estimated by applying Average 
Wholesale Price to each patient’s observed treatment course (initial dose, dose changes, 
and treatment duration). Ofﬁce visit and procedure costs were based on US private 
insurance reimbursement. Hospitalization costs were based on HCUP National Inpa-
tient Sample average charges associated with AE diagnosis; cost-to-charge ratios were 
applied. ER visit costs were based on national averages from Medical Expenditure 
Panel Survey. RESULTS: Median treatment duration was10.5 months (sunitinib), 8.1 
months (sorafenib), and 7.9 months (bevacizumab). Total health care costs PPPM 
(mean ± SD) were $7,945 ± 2,993 (sunitinib), $6,990 ± 3,073 (sorafenib), and $15,189 
± 1,859 (bevacizumab). AI drug costs comprised 71% (sunitinib), 75% (sorafenib), 
and 90% (bevacizumab) of the total PPPM cost. All-grade AE costs PPPM were $729 
± SD (sunitinib), $636 ± SD (sorafenib), and $291 ± SD (bevacizumab). Given the 
median treatment durations, the total cost over the course of ﬁrst-line AI treatment is 
estimated at $83,422 (sunitinib), $56,622 (sorafenib), and $119,996 (bevacizumab), 
including AE treatment cost of $7,656 (sunitinib), $5,149 (sorafenib), and $2,297 
(bevacizumab). CONCLUSIONS: AI drug cost was a major contributor to the total 
health care PPPM cost in patients with mRCC, especially for patients receiving beva-
cizumab. This retrospective study is limited by small sample sizes. Future studies 
examining comparative cost-effectiveness of these AIs are warranted to evaluate clini-
cal and economic effects of these AIs.
